---
document_datetime: 2024-10-21 11:04:46
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/leflunomide-medac-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: leflunomide-medac-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.0474457
conversion_datetime: 2025-12-18 21:09:21.876299
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Leflunomide medac

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0042               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 18/10/2024                          |                                             | PL                               |           |
| IA/0041              | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                    | 16/08/2024                          |                                             | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/1837/ 202309   | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                    | 30/05/2024   | 24/07/2024   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1837/202309.   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| N/0040               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 18/03/2024   | 24/07/2024   | PL            |                                                                                                                                             |
| N/0038               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 31/10/2023   | 24/07/2024   | PL            |                                                                                                                                             |
| N/0037               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 07/03/2023   | 04/05/2023   | PL            |                                                                                                                                             |
| N/0036               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 03/02/2023   | 04/05/2023   | PL            |                                                                                                                                             |
| IB/0035              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/05/2022   | 04/05/2023   | SmPC and PL   |                                                                                                                                             |
| PSUSA/1837/ 202009   | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                    | 06/05/2021   | n/a          |               | PRAC Recommendation - maintenance                                                                                                           |
| IAIN/0033            | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                          | 22/12/2020   | n/a          |               |                                                                                                                                             |
| IB/0032              | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                            | 08/07/2020   | 24/06/2021   | SmPC, Annex   |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                    | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                              |            |            | II, Labelling and PL   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0031            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                             | 21/11/2019 | n/a        |                        |                                   |
| IA/0030            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                            | 14/06/2018 | n/a        |                        |                                   |
| PSUSA/1837/ 201709 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                               | 12/04/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0029             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                        | 30/01/2018 | 21/06/2018 | PL                     |                                   |
| IAIN/0027/G        | This was an application for a group of variations. B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 18/07/2017 | 21/06/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/1837/ 201609 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                               | 06/04/2017 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| PSUSA/1837/ 201509   | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                                                     | 14/04/2016   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                              |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0025            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                | 10/12/2015   | 15/07/2016 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                |
| IA/0023              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                | 31/07/2015   | 15/07/2016 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                |
| IA/0022              | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                   | 08/07/2015   | n/a        |                                  |                                                                                                                                                                                                                                                                                                |
| IA/0021/G            | This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 08/07/2015   | n/a        |                                  |                                                                                                                                                                                                                                                                                                |
| PSUSA/1837/ 201409   | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                                                     | 10/04/2015   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                              |
| R/0019               | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                       | 22/01/2015   | 23/03/2015 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considered that the benefit-risk balance of Leflunomide Medac in the approved indication remains favourable and therefore recommended |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                              |            |            |                                  | the renewal of the marketing authorisation with unlimited validity.                                                                                                                                       |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 29/09/2014 | 23/03/2015 | SmPC and PL                      |                                                                                                                                                                                                           |
| IB/0017            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 09/09/2014 | n/a        |                                  |                                                                                                                                                                                                           |
| IAIN/0016/G        | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release     | 10/06/2014 | 23/03/2015 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                           |
| PSUSA/1837/ 201309 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                    | 10/04/2014 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                         |
| IB/0015            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                               | 23/03/2014 | 23/03/2015 | SmPC and PL                      | To add the patent protected indication 'psoriatic arthritis'. Subsequently the RMP was updated and adapted to the current format. In addition, the SmPC was brought in line with the latest QRD template. |
| X/0012/G           | This was an application for a group of variations. - To add a new strength.                                                                                                                                                                                  | 30/05/2013 | 25/07/2013 | SmPC, Annex II, Labelling        | Please refer to the assessment report Leflunomide medac- H-1227-X-12-G-AR-Extension.                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | - To extend the shelf life of the finished product. - To replace the DDPS with a summary of PhV system. - To make some editorial changes. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) Annex I_2.(c) Change or addition of a new strength/potency   |            |            | and PL                           |                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0013 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                  | 28/01/2013 | 25/07/2013 | SmPC and PL                      | Update of Sections 4.4 and 4.8 of the SmPC to add cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis and warn physicians about these skin reactions in accordance with the reference product. The Package Leaflet was updated accordingly.                                                                                                                                         |
| N/0010  | \"Update of the local representatives contact details for France and Italy.\" Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                    | 17/09/2012 | 29/10/2012 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0009 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                  | 13/06/2012 | 29/10/2012 | SmPC, Annex II, Labelling and PL | Implementation of changes approved in reference product - update of section 4.4 to add a warning for peripheral neuropathy and the frequency of this event has been changed to 'common' in section 4.8 as requested by CHMP. The PIL has been updated accordingly. Further updates concern the implementation of the latest QRD template. In addition, the MAH updated the list of local representatives |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       | for Cyprus and Iceland.                                                                                                                                                                                                                                                                                                                                                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0008 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                | 05/12/2011 | 30/01/2012 | SmPC                  | Update of section 4.4 of the SmPC regarding the risk of leflunomide use in combination with biologicals following the CHMP assessment of the COLEBI study (FU2 038.1) as implemented in the originator product Arava II-49.                                                                                                                                                    |
| IB/0007 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                | 15/09/2011 | n/a        | SmPC and PL           | Update of sections 4.2 and 5.1 of the SmPC to reflect the outcome of the clinical study R01143 (LEADER) regarding the use of a loading dose, as requested by CHMP. The MAH also took the opportunity to make minor linguistic corrections to align with the reference product and made changes to the contact details of the local representatives in the package leaflets.    |
| IB/0003 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 30/08/2011 | n/a        | SmPC, Annex II and PL | Implementation of changes approved in reference product - update of section 4.4 to amend the warning for interstitial lung disease (ILD) as requested by CHMP. The PIL was revised accordingly. In addition the description of the risk of teratogenicity in the PIL was strengthened. Further updates concern the Annex IIB and the implementation of the latest QRD template |
| IA/0006 | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                               | 05/08/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IA/0005   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                    | 30/06/2011   | n/a   |                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------|
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 23/06/2011   | n/a   | SmPC, Annex II, Labelling and PL |